Peter Mac researchers in global top 1%
03 December 2024
Peter Mac is proud to announce that five researchers have been named in Clarivate’s prestigious list of the top 1 per cent most cited researchers worldwide for 2024.
Their profound influence on their field, as evidenced by citation metrics in top-tier journals, highlights the global impact of their work and underscores Peter Mac’s commitment to advancing cancer research and care.
Peter Mac’s Acting Director of Cancer Research Professor Mark Dawson said he was “incredibly proud to see our people are driving research that’s improving outcomes for patients everywhere”.
“We congratulate each of the researchers on this incredible achievement and their ground-breaking work that’s having a global impact,” Professor Dawson said.
“It is a testament to the collaborative and interdisciplinary environment fostered at Peter Mac, where world-class research translates into life-saving care.”
By country, Australia ranked fifth overall in the list, while the United States was in the number one spot.
Read about each of Peter Mac’s top researchers below:
Associate Professor Paul Beavis
Professor Beavis’s groundbreaking work focuses on T-cell immunotherapy, exploring innovative ways to harness the immune system to target cancer. His research has significantly advanced our understanding of immune responses in solid tumors, driving new strategies for cancer treatment.
A pioneer in cellular immunotherapy, Professor Darcy is renowned for his contributions to CAR T cell research. His studies aim to improve the efficacy and accessibility of these therapies, particularly for patients with otherwise treatment-resistant cancers.
An internationally recognised leader in breast cancer research, Professor Loi’s work on the role of the immune system in breast cancer has shaped clinical practice. Her insights into biomarkers and immunotherapy for triple-negative breast cancer are paving the way for more personalised treatment approaches.
Professor Sandhu is a trailblazer in clinical trials and translational research, particularly in the fields of prostate cancer and melanoma. Her leadership in evaluating novel therapies has brought cutting-edge treatments closer to patients, improving outcomes and quality of life.
A leading authority in thoracic oncology, Professor Solomon’s work has been instrumental in understanding lung cancer biology and developing targeted therapies. His research continues to transform the treatment landscape for lung cancer patients worldwide.